Future routine HER2 assessment could lower the threshold for adjuvant radiotherapy, as a retrospective analysis of the UK/ANZ DCIS randomized trial population showed a higher benefit from adjuvant radiotherapy in HER2-positive DCIS than in HER2-negative DCIS [12]. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.